Wykoff, Charles C <br/><br/>
SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results.  [electronic resource] 

 -  Ophthalmic surgery, lasers & imaging retina   
 - 121-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Historical Article; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2325-8179 
<br/><br/><label>Standard No.: </label>10.3928/23258160-20130313-04  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Drug Resistance<br/>Female<br/>Fluorescein Angiography<br/>History, 18th Century<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Prospective Studies<br/>Ranibizumab<br/>Refraction, Ocular<br/>Tomography, Optical Coherence<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology<br/>Wet Macular Degeneration--diagnosis